retatrutide clinical trial results weight loss Eli Lilly's Phase 3 studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial loss. Read about the work via the link in the comments Retatrutide vs Tirzepatide: Which Peptide

In einer Studie wurde herausgefunden, dass die kombinierte Einnahme beider Prparate ber einen Zeitraum von zwei Monaten die Laktatwerte und die Kopfschmerzen senken konnte

Why are people talking about compounded GLP-1s

They need to be prescribed appropriately, with tailored wraparound support alongside them, to ensure people can fully benefit and maintain weight loss for as long as possible when they stop taking the medication. More on GLP-1s: Something Grim Is Happening to People Who Go Off GLP-1s

The update comes soon after the World Health Organization updated its guidelines for obesity treatment, citing the combination of GLP-1 drugs, a healthy diet and exercise being integral for success among patients

The STEP 1 trial of injectable semaglutide 2.4 mg reported a 7.0% discontinuation rate due to adverse events